Hypoxyprobe，Inc产品代理
Hypoxyprobe，Inc产品代理
Hypoxyprobe, Inc. 是由北卡罗来纳大学教堂山分校放射肿瘤学系的 James Raleigh 博士和当时位于北卡罗来纳州研究三角公园的 NPI 合作产生的。
UNC Chapel Hill 和 NPI 之间的合作最初侧重于肿瘤缺氧的临床研究。 NPI 大规模生产盐酸匹莫硝唑，罗利博士提供专利抗体试剂，用于检测匹莫硝唑与人类肿瘤缺氧细胞的结合。
狗、大鼠和小鼠的临床前研究使科学界对 pimonidazole HCl 作为一般缺氧标志物越来越感兴趣，2002 年 NPI 向 Chemicon International 颁发了为期五年的独家许可，以销售有限系列的动物用 Hypoxyprobe 试剂. 2006 年，预计需要扩大 Hypoxyprobe 试剂系列，NPI 终止了 Chemicon 的许可并成立了 Hypoxyprobe, Inc. 以开发用于动物和临床研究的增强型试剂系列。
公司目前专注于开发基于匹莫硝唑核心结构的非侵入性缺氧标记物和缺氧依赖性细胞毒素。
Hypoxyprobe, Inc. is a small company dedicated to providing tools for the diagnosis and treatment of malignant and normal
tissue diseases in which oxygen regulation is disturbed. The company is located at 121 Middlesex Turnpike, Burlington, Massachusetts, USA 01803 and is a spin-off of the Hypoxyprobe Division of Natural Pharmacia International, Inc. (NPI).
Hypoxyprobe, Inc. arose from a collaboration between Dr. James Raleigh in the Department of Radiation Oncology at the University of North Carolina at Chapel Hill and NPI which at the time was located in the Research Triangle Park, North Carolina.
The collaboration between UNC Chapel Hill and NPI at first focused on clinical studies of tumor hypoxia. NPI manufactured pimonidazole HCl on a large scale and Dr. Raleigh provided patented antibody reagents for detecting the binding of pimonidazole to hypoxic cells in human tumors.
Preclinical studies in dogs, rats and mice generated a growing interest among the scientific community in pimonidazole HCl as a hypoxia marker in general and in 2002 NPI issued a five-year exclusive license to Chemicon International to market a limited line of Hypoxyprobe reagents for animal use. In 2006, anticipating a need for an expanded line of Hypoxyprobe reagents, NPI ended Chemicon’s license and established Hypoxyprobe, Inc. to develop an enhanced line of reagents for both animal and clinical studies.
The Company is now focused on developing non-invasive hypoxia markers and hypoxia dependent cytotoxins based on the pimonidazole core structure.
